Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Multi-Center Clinical Study to Harvest and Characterize Circulating Tumor Cells from Patients with Metastatic Breast Cancer Using the Parsortix® PC1 System.
Cohen EN, Jayachandran G, Moore RG, Cristofanilli M, Lang JE, Khoury JD, Press MF, Kim KK, Khazan N, Zhang Q, Zhang Y, Kaur P, Guzman R, Miller MC, Reuben JM, Ueno NT. Cohen EN, et al. Among authors: jayachandran g. Cancers (Basel). 2022 Oct 26;14(21):5238. doi: 10.3390/cancers14215238. Cancers (Basel). 2022. PMID: 36358657 Free PMC article.
Gene expression profiling of circulating tumor cells captured by MicroCavity Array is superior to enumeration in demonstrating therapy response in patients with newly diagnosed advanced and locally advanced non-small cell lung cancer.
Cohen EN, Jayachandran G, Gao H, Peabody P, McBride HB, Alvarez FD, Bravo PL, Qiao W, Liu S, Yao L, Lin SH, Reuben JM. Cohen EN, et al. Among authors: jayachandran g. Transl Lung Cancer Res. 2023 Jan 31;12(1):109-126. doi: 10.21037/tlcr-22-314. Epub 2023 Jan 16. Transl Lung Cancer Res. 2023. PMID: 36762061 Free PMC article.
The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate-resistant HER2-overexpressing breast cancer.
Lee J, Kida K, Koh J, Liu H, Manyam GC, Gi YJ, Rampa DR, Multani AS, Wang J, Jayachandran G, Lee DW, Reuben JM, Sahin A, Huo L, Tripathy D, Im SA, Ueno NT. Lee J, et al. Among authors: jayachandran g. J Exp Clin Cancer Res. 2024 Aug 21;43(1):236. doi: 10.1186/s13046-024-03143-3. J Exp Clin Cancer Res. 2024. PMID: 39164784 Free PMC article.
Paediatric pulmonary disease-are we diagnosing it right?
Rajendran P, Thomas SV, Balaji S, Selladurai E, Jayachandran G, Malayappan A, Bhaskar A, Palanisamy S, Ramamoorthy T, Hasini S, Hissar S. Rajendran P, et al. Among authors: jayachandran g. Front Pediatr. 2024 Apr 10;12:1370687. doi: 10.3389/fped.2024.1370687. eCollection 2024. Front Pediatr. 2024. PMID: 38659699 Free PMC article.
Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy.
Dai B, Yan S, Lara-Guerra H, Kawashima H, Sakai R, Jayachandran G, Majidi M, Mehran R, Wang J, Bekele BN, Baladandayuthapani V, Yoo SY, Wang Y, Ying J, Meng F, Ji L, Roth JA. Dai B, et al. Among authors: jayachandran g. PLoS One. 2015 Jun 8;10(6):e0123967. doi: 10.1371/journal.pone.0123967. eCollection 2015. PLoS One. 2015. PMID: 26053020 Free PMC article.
Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans.
Lu C, Stewart DJ, Lee JJ, Ji L, Ramesh R, Jayachandran G, Nunez MI, Wistuba II, Erasmus JJ, Hicks ME, Grimm EA, Reuben JM, Baladandayuthapani V, Templeton NS, McMannis JD, Roth JA. Lu C, et al. Among authors: jayachandran g. PLoS One. 2012;7(4):e34833. doi: 10.1371/journal.pone.0034833. Epub 2012 Apr 25. PLoS One. 2012. PMID: 22558101 Free PMC article. Clinical Trial.
34 results